Phio Pharmaceuticals Corp (PHIO): RXII Key Highlights for Jefferies Health...

Send PM Follow Ignore

Followers	35
Posts	1771
Boards Moderated	0
Alias Born	09/25/2012

Inoviorulez

Re: None

Tuesday, 06/03/2014 8:37:16 AM

Tuesday, June 03, 2014 8:37:16 AM

RXII Key Highlights for Jefferies Healthcare Conference Presentation

1. Because of LPC deal RXII now has enough cash until Q2 of 2017

2. Pictures are coming in for phase 2a hypertrophic scar results and trial still double-blinded but either RXI-109 is dramatically reducing scars or placebo is. My assumption would be they are seeing better reduction in scars with RXI-109 and not placebo that means the results are positive.

3. New move to lab will be complete by Fall in which time they will announce other phase 2 clinical candidates

4. Also the new move to new lab will allow company to create topical form for RXI-109 because it is soluble. Company is excited about this because this brings RXII to a new level as a company

5. Phase 2a breast scar revision surgery study was supposed to start Q3 2014 but being moved to Q4 2014. But this is good news because company has decided to expand on this study and target other parts of the body other than just breast scars. That to me means RXI-109 is working well and that should be construed as bullish.